Fluticasone propionate in the topical treatment of skin diseases



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

В обзоре приведены данные, обобщающие многолетний опыт местного применения флутиказона пропионата при лечении таких заболеваний, как атопический дерматит, экзема, псориаз и др. Представлены основные результаты клинических исследований по его эффективности и безопасности.

About the authors

O G Elisyutina

Institute of Immunology

Email: el-olga@yandex.ru
Institute of Immunology

References

  1. Barnes P. J. New directions in allergic diseases: mechanism-based antiinflammatory therapies. J. Allergy Clin. Immunology, 2000, v. 106, p. 5-16.
  2. Аллергология и иммунология. Национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.
  3. Атопический дерматит: рекомендации для практических врачей. Российский национальный согласительный документ по атопическому дерматиту. Под ред. Р.М. Хаитова, А.А. Кубановой. М. «Фармарус-принт».2002, 192 с.
  4. Akdis C.A. Review article Diagnosis and treatment of atopic dermatitis in children and adults: Europian Academy of Allergology and Clinical Immunology American Academy of Allergy, Asthma and Immunology PRACTALL Consensus report. Allergy. 2006, v. 61, p. 969-987.
  5. Ponec M. Glucocorticoids and cultured human skin cells: specific intracellular binding and structure-activity relationships. Br. J. Dermatol. 1982, v. 107, Suppl. 23, p. 24-29.
  6. Roeder A., Schaller M., Schäfer-Korting M., Korting H.C. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin. Pharmacol. Physiol. 2005, Jan-Feb, v. 18 (1), p. 3-11.
  7. Hogger P., Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994, v. 59, p. 597-602.
  8. De Bosscher K., Van den Berghe W., Haegeman G. The interplay between the glucorticoid receptor and nuclear factor-kappa B or activator protein-1 : Molecular mechanisms for gene repression. Endocr. Rev. 2003, v. 24, p. 488-522.
  9. Johnson M. Anti-inflammatory properties offluticasone propionate. Int. Arch. Allergy Immunol. 1995, v. 107, p. 439-440.
  10. Cornell R.C., Stoughton R.B. Correlation ofthe vasoconstriction assay and clinical activity in psoriasis. Arch. Dermatol. 1985, v. 121, p. 63-67.
  11. Preclinical data on file, GlaxoSmithKline GmbH & Co KG, Munich, Germany.
  12. Falcoz C., Oliver R., McDowall J.E., Ventresca P. et al. Bioavailability of orally administered micronised fluticasone propionate. Clin. Pharmacokinet. 2000, v. 39, p. 9-15.
  13. Young M.M.R., Sohail S., Harding S.M. A comparison ofthe systemic absorption of fluticasone propionate and betametha-sone valerate after topical application of cream formulations. Br. J. Dermatol. 1994, v. 131, p. 35-36.
  14. Juhlin L. Comparison of fluticasone propionate cream, 0,05%, and hydrocortisone-17-butyrate cream, 0,1%, in the treatment of eczema. Cutis. 1996, v. 57, p. 51-56.
  15. Dykes P.J., Marks R., Hill S., Mills C., Eastwood R. The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Clin. Exp. Dermatol. 1996, v. 21, p. 180-184.
  16. Tan C.Y., Marks R., Payne P. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J. Invest Dermatol. 1981, v. 76, p. 126-128.
  17. Friedlander S.F., Hebert A.A., Allen D.B. Fluticasone Pediatrics Safety Study Group: Safety of fluticasone propionate cream 0,05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J. Am. Acad. Dermatol. 2002, v. 46, p. 387-393.
  18. Tan M.H., Lebwohl M., Esser A.C., Wei H. The penetration of 0,005% fluticasone propionate ointment in eyelid skin. J. Am. Acad. Dermatol. 2001, v. 45, p. 392-396.
  19. Wilkinson S.M., Jones M.F. Corticosteroid usage and binding to arginine: Determinants of corticosteroid hypersensitivity. Br. J. Dermatol. 1996, v. 135, p. 225-230.
  20. Goossens A., Huygens S., Matura M., Degreef H. Fluticasone propionate: A rare contact sensitizer. Eur. J. Dermatol. 2001, v. 11, p. 29-34.
  21. Delescluse J., van der Endt J.D. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0,005%, and betamethasone-17, 21-dipropionate ointment, 0,05%, in the treatment of eczema. Cutis. 1996, v. 57, p. 32-38.
  22. Tan M.H., Meador S.L., Singer G., Lebwohl M.G. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0,005%, in patients with atopic dermatitis of the face and intertriginous areas. Int. J. Dermatol. 2002, v. 41, p. 804-809.
  23. Wolkerstorfer A., Strobos M.A., Glazenburg E.J., Mulder P.G., Oranje A.P. Fluticasone propionate 0,05% cream once daily versus clobetasone butyrate 0,05% cream twice daily in children with atopic dermatitis. J. Am. Acad. Dermatol. 1998, v. 39, p. 226-231.
  24. Pei A.Y., Chan H.H., Ho K.M. The effectiveness of wet wrap dressings using 0,1% mometasone furoate and 0,005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr. Dermatol. 2001, v. 18, p. 343-348.
  25. Van Der Meer J.B., Glazenburg E.J., Mulder P.G., Eggink H.F., Coenraads P.J. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br. J. Dermatol. 1999, v. 140, p. 1114-1121.
  26. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br. J. Dermatol. 2002, v. 147б, p. 528-537.
  27. Kirkup M.E., Birchall N.M., Weinberg E.G., Helm K., Kennedy C.T Acute and maintenance treatment of atopic dermatitis in children - Two comparative studies with fluticasone propionate (0,05%) cream. J. Dermatol. Treat. 2003, v. 14, p. 141-148.
  28. Olsen E.A. Efficacy and safety of fluticasone propionate 0,005% ointment in the treatment of psoriasis. Cutis. 1996, Feb, v. 57, p. 57-61.
  29. Callen J. Comparison of safety and efficacy of fluticasone propionate cream, 0,05%, and betamethasone valerate cream, 0,1%, in the treatment of moderate-to-severe psoriasis. Cutis. 1996, v. 57, p. 45-50.
  30. Westerhof W., Nieuweboer-Krobotova L., Mulder P.G., Glazenburg E.J. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch. Dermatol. 1999, v. 135, p. 1061-1066.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies